Literature DB >> 34988720

Neuro-oncology and supportive care: the role of the neurologist.

Natalie E Stec1, Tobias Walbert2,3.   

Abstract

The diagnosis of a brain tumor is a life-changing event for patients and their families. Despite numerous treatment advances, malignant brain tumors are universally incurable and long-term survival is limited. Treatment response, prognosis, and survival depend on underlying histopathology and recently defined molecular features. Patients suffer from a disproportionately high symptom burden throughout the disease trajectory and at the end of life. Pronounced neurologic decline and psychological distress significantly impair quality of life (QoL) and impose high supportive care needs relative to other systemic cancers. Palliative interventions addressing brain tumor-specific symptoms, such as seizures, cognitive dysfunction, and headaches, are paramount to maintaining QoL. In the terminal phase of illness, most brain tumor patients lose the ability to communicate and participate in end-of-life decision-making. The benefits of advance care planning and early integration of specialized palliative care are well-established in other systemic cancers and have received wider recognition in neuro-oncology. We review how to approach neurological symptoms in brain tumor patients, as well as address prognosis and advance care planning with the goal of improving QoL for patients and caregivers.
© 2022. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  Brain tumor; End of life; Glioblastoma; Palliative care; Quality of life; Supportive care

Mesh:

Year:  2022        PMID: 34988720     DOI: 10.1007/s10072-021-05862-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.830


  77 in total

Review 1.  A consensus review on the development of palliative care for patients with chronic and progressive neurological disease.

Authors:  D J Oliver; G D Borasio; A Caraceni; M de Visser; W Grisold; S Lorenzl; S Veronese; R Voltz
Journal:  Eur J Neurol       Date:  2015-10-01       Impact factor: 6.089

2.  Impact of provider level, training and gender on the utilization of palliative care and hospice in neuro-oncology: a North-American survey.

Authors:  Tobias Walbert; Michael Glantz; Lonni Schultz; Vinay K Puduvalli
Journal:  J Neurooncol       Date:  2015-10-30       Impact factor: 4.130

Review 3.  End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic literature review.

Authors:  Tobias Walbert; Muhib Khan
Journal:  J Neurooncol       Date:  2014-02-13       Impact factor: 4.130

4.  The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms.

Authors:  Terri S Armstrong; Elizabeth Vera-Bolanos; Alvina A Acquaye; Mark R Gilbert; Harshad Ladha; Tito Mendoza
Journal:  Neuro Oncol       Date:  2015-08-19       Impact factor: 12.300

5.  Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.

Authors:  Roger Stupp; Sophie Taillibert; Andrew Kanner; William Read; David Steinberg; Benoit Lhermitte; Steven Toms; Ahmed Idbaih; Manmeet S. Ahluwalia; Karen Fink; Francesco Di Meco; Frank Lieberman; Jay-Jiguang Zhu; Giuseppe Stragliotto; David Tran; Steven Brem; Andreas Hottinger; Eilon D. Kirson; Gitit Lavy-Shahaf; Uri Weinberg; Chae-Yong Kim; Sun-Ha Paek; Garth Nicholas; Jordi Bruna; Hal Hirte; Michael Weller; Yoram Palti; Monika E. Hegi; Zvi Ram
Journal:  JAMA       Date:  2017-12-19       Impact factor: 56.272

6.  A proposed framework of supportive and palliative care for people with high-grade glioma.

Authors:  Jennifer Philip; Anna Collins; Caroline Brand; Vijaya Sundararajan; Carrie Lethborg; Michelle Gold; Rosalind Lau; Gaye Moore; Michael Murphy
Journal:  Neuro Oncol       Date:  2018-02-19       Impact factor: 12.300

Review 7.  European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma.

Authors:  Andrea Pace; Linda Dirven; Johan A F Koekkoek; Heidrun Golla; Jane Fleming; Roberta Rudà; Christine Marosi; Emilie Le Rhun; Robin Grant; Kathy Oliver; Ingela Oberg; Helen J Bulbeck; Alasdair G Rooney; Roger Henriksson; H Roeline W Pasman; Stefan Oberndorfer; Michael Weller; Martin J B Taphoorn
Journal:  Lancet Oncol       Date:  2017-06       Impact factor: 54.433

8.  Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis.

Authors:  Michael T C Poon; Cathie L M Sudlow; Jonine D Figueroa; Paul M Brennan
Journal:  Sci Rep       Date:  2020-07-15       Impact factor: 4.379

9.  Caregiver burden by treatment and clinical characteristics of patients with glioblastoma.

Authors:  Trang H Au; Connor Willis; Maija Reblin; Katherine B Peters; Phioanh Leia Nghiemphu; Jennie W Taylor; Howard Colman; Adam L Cohen; D Ryan Ormond; Arnab Chakravarti; Nicole Willmarth; Jyothi Menon; Junjie Ma; Hillevi Bauer; Alexandre H Watanabe; Cornelia M Ulrich; Prianka Singh; Alexander Marshall; Beata Korytowsky; David Stenehjem; Diana Brixner
Journal:  Support Care Cancer       Date:  2021-09-11       Impact factor: 3.603

Review 10.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Pieter Wesseling; Daniel J Brat; Ian A Cree; Dominique Figarella-Branger; Cynthia Hawkins; H K Ng; Stefan M Pfister; Guido Reifenberger; Riccardo Soffietti; Andreas von Deimling; David W Ellison
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 13.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.